Clinical trials: Mild Neurocognitive Disorder
Alzheimer Disease
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer's Disease.
- Trial name
- NCT04251182
- Testing
- 15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- T3D Therapeutics, Inc.
Alzheimers Disease
A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease
The primary purpose of this study is to evaluate the efficacy of LEQEMBI in participants with early Alzheimer's disease (AD) indicated per Canada Product Monograph (APOE4 non-carriers and heterozygotes; indicated population)…
- Trial name
- NCT07864623
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Eisai Inc.
Dementia With Lewy Bodies
Expanded Access Program for CT1812 (Zervimesine)
This is a multi-center, open label, expanded access program (EAP) that will provide 100 mg CT1812 for up to one year to participants with mild-to-moderate DLB.
- Trial name
- NCT06961760
- Testing
- zervimesine
- Where
- 8 sites in United States
- Sponsor
- Cognition Therapeutics
Fall, Mild Cognitive Impairment (MCI)
Digital STEADI Efficacy
The aging of the U.S. population, combined with health care workforce shortages and insufficient access to effective fall prevention and exercise programs, has contributed to a high burden of fall-related injuries in older…
- Conditions
- Fall, Mild Cognitive Impairment (MCI), Aging
- Trial name
- NCT07852650
- Testing
- Digital STEADI-1, STEADI Standard of Care, Digital STEADI-2
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Friendi.fi Corporation
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236574
- Testing
- Galantamine hydrobromide
- Volunteers
- 974 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimers Disease
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to…
- Trial name
- NCT04639050
- Testing
- RO7126209
- Where
- 37 sites in United States, Australia and 7 more
- Volunteers
- 241 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
The purpose of this study was to evaluate the efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild-moderate Alzheimer's disease.
- Trial name
- NCT00742417
- Testing
- Albutein 5%, Control
- Where
- 4 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Instituto Grifols, S.A.
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Dementia Alzheimer's Type
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Primary Objective: To demonstrate the efficacy of at least one dose of SAR110894 (H3 receptor antagonist) in comparison to placebo on cognitive performance in patients with mild to moderate Alzheimer's disease (AD) while on…
- Trial name
- NCT01266525
- Testing
- SAR110894, Donepezil
- Where
- 82 sites in United States, Australia and 7 more
- Volunteers
- 291 people
- Sponsor
- Sanofi
Neurocognitive Disorders, Mild, Cognitive Impairment, Mild
Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders
This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such…
- Conditions
- Neurocognitive Disorders, Mild, Cognitive Impairment, Mild, Depression Mild, Apathy
- Trial name
- NCT07237009
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- KompanionCare SAS
Mild Cognitive Impairment, Dementia
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
This retrospective study is a more extensive, confirmatory analysis of the cognitive and functional outcomes initially seen in 2 groups of MCI/dementia patients in Springfield, MA and compares specialized dementia care and a…
- Conditions
- Mild Cognitive Impairment, Dementia, Hypoxia, Hyperhomocysteinemia
- Trial name
- NCT02860338
- Volunteers
- 900 people
- Sponsor
- Clionsky Neuro Systems Inc.
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI)
Evaluation of SCALE PET Software for Quantitative Brain PET Analysis in Alzheimer's Disease
The goal of this study is to learn if medical image analysis software, Neurophet SCALE PET, can enhance readers' amyloid beta positivity performance in people with Alzheimer's Disease.
- Trial name
- NCT07417540
- Testing
- Neurophet SCALE PET
- Where
- South Korea
- Volunteers
- 190 people
- Sponsor
- NEUROPHET
Alzheimer's Disease
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
The purpose of the study is to evaluate safety and the pharmacodynamic effects of BMS-241027 on cerebrospinal fluid (CSF) Tau, connectivity magnetic resonance imaging (MRI), and computerized cognitive tests in mild Alzheimer's…
- Trial name
- NCT01492374
- Testing
- BMS-241027
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer's Disease
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
The main purpose of this study is to evaluate the safety and efficacy of Octohydroaminoacridine Succinate tablets and find the optimal dose in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01569516
- Testing
- Octohydroaminoacridine Succinate Tablets
- Where
- 13 sites in China
- Volunteers
- 288 people
- Sponsor
- Changchun Huayang High-tech Co., Ltd
Mild Cognitive Impairment, Alzheimer's Disease
Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements
In a retrospective analysis of data from 1100 patients, disease-delaying effects of Cerefolin®/CerefolinNAC® were examined in terms of cognition.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease Related Disorders
- Trial name
- NCT01745198
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Pamlab, Inc.
Alzheimer Disease, Mild Cognitive Impairment
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States.
- Trial name
- GERAS-US (NCT02951598)
- Testing
- Florbetapir F 18 PET Scan
- Where
- 77 sites in United States
- Volunteers
- 1,400 people
- Sponsor
- Eli Lilly and Company
Dementia, Alzheimer Disease 1
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.
- Conditions
- Dementia, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT03806478
- Testing
- APH-1105
- Volunteers
- 60 people
- Sponsor
- Aphios
Alzheimer Disease
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
- Trial name
- NCT04079803
- Testing
- Simufilam 100 mg tablet, Simufilam 50 mg oral tablet
- Where
- 9 sites in United States
- Volunteers
- 64 people
- Sponsor
- Cassava Sciences, Inc.
Alzheimer's Disease
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).
- Trial name
- NCT00679627
- Testing
- Galantamine
- Where
- 95 sites in Czechia, Estonia and 10 more
- Volunteers
- 2,051 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Disease
Efficacy and Safety of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
The purpose of this clinical trial is to exploratively evaluate the efficacy and safety of NVP -NK4146 in improving mild cognitive impairment (MCI) in patients with due to Alzheimer's disease (AD) compared to placebo
- Trial name
- NCT06761066
- Testing
- NVP-NK4146
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- NVP Healthcare